ViroChannel brings together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.
Debating The Merits of Monotherapy For HIV
with Dr. Réjean Thomas, Dr. José Arribas and Dr. Laurent Cotte
- Reasons doctors are reluctant to use HIV monotherapy
- Which patients are suitable for monotherapy
- Reports of extended experience with HIV monotherapy
- Long term toxicity associated with cART
- The potential advantages of monotherapy for aging patients
- HIV monotherapy and neurodegenerative disease
This activity is supported by
an educational grant from:
The need to switch patients from combination antiretroviral therapy (cART) to HIV monotherapy may become less urgent as newer, less toxic cART regimens are developed; however, there will likely continue to be concerns about toxicity from long term use of HIV medications.
The doctors review concerns about the safety of returning to cART after a monotherapy regimens, the efficacy of monotherapy, and potential problems with resistance before transitioning into a discussion of some of the systemic barriers that work against switching patients to monotherapy – such as why multi-drug regimens are the clinical default.
Finally, they share their concerns about aging patients with HIV and, in particular, the potential for neurocognitive impairment with decades long use of cART.
Réjean Thomas, MD
CEO | Founder
Clinique médicale l’Actuel:
Centre of Excellence HIV–STI–Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Laurent Cotte, MD
Tropical and Infectious Disease Department
Croix-Rousse Hospital (CHU Lyon)
José Arribas, MD
Autonoma University School of Medicine
HIV unit of La Paz Hospital
You must be logged in to view the complete program
ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Réjean Thomas, MD has a financial interest/relationship or affiliation: Janssen, Abbott, Merck, BMS, Gilead Sciences, ViiV Healthcare.
José Arribas, MD has a financial interest/relationship or affiliation: Tibotec, Janssen, Abbott, BMS, Gilead Sciences, MSD, ViiV Healthcare.
Laurent Cotte, MD has a financial interest/relationship or affiliation: Janssen, Gilead Sciences.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.